Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
Targeting the renin-angiotensin-aldosterone system (RAAS), specifically the effector peptide angiotensin II (Ang II), represents a major opportunity for slowing the progression of cardiovascular disease (CVD) and, in turn, reducing the risk of morbidity and mortality. Inhibition of angiotensin-conve...
Main Authors: | Georg Nickenig, Jan Östergren, Harry Struijker-Boudier |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publications
2006-03-01
|
Series: | Journal of the Renin-Angiotensin-Aldosterone System |
Online Access: | http://jra.sagepub.com/content/7/1_suppl/S1.full.pdf |
Similar Items
-
Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
by: Georg Nickenig, et al.
Published: (2006-03-01) -
Angiotensin receptor blockers in heart failure
by: Jan Östergren, et al.
Published: (2003-09-01) -
Angiotensin II receptor blockers and cardiovascular outcomes: The evidence now and in the future
by: Michael Weber
Published: (2001-06-01) -
Angiotensin II receptor blockers and cardiovascular outcomes: the evidence now and in the future
by: Michael Weber
Published: (2001-06-01) -
Use of angiotensin receptor blockers in cardiovascular protection. Current evidence and future directions
by: M. A. Munger
Published: (1970-01-01)